These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9847048)
21. Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride. Koch HJ; Szecsey A; Vogel M; Fischer-Barnicol D Int J Clin Pract; 2003 Mar; 57(2):147-9. PubMed ID: 12661802 [TBL] [Abstract][Full Text] [Related]
22. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962 [TBL] [Abstract][Full Text] [Related]
24. Antipsychotic medication: clinical guidelines for maintenance therapy. Johnson DA J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281 [TBL] [Abstract][Full Text] [Related]
25. [Atypical neuroleptics in child- and adolescent psychiatry]. Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):45-57. PubMed ID: 10746298 [TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. Srisurapanont M; Maneeton N J Med Assoc Thai; 1999 Apr; 82(4):341-6. PubMed ID: 10410494 [TBL] [Abstract][Full Text] [Related]
28. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS Am J Psychiatry; 1998 Apr; 155(4):565-7. PubMed ID: 9546009 [TBL] [Abstract][Full Text] [Related]
29. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Peritogiannis V; Tsouli S J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463 [No Abstract] [Full Text] [Related]
30. Severe akathisia during olanzapine treatment of acute schizophrenia. Jauss M; Schröder J; Pantel J; Bachmann S; Gerdsen I; Mundt C Pharmacopsychiatry; 1998 Jul; 31(4):146-8. PubMed ID: 9754850 [TBL] [Abstract][Full Text] [Related]
32. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534 [TBL] [Abstract][Full Text] [Related]
33. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Bilici M; Cakirbay H; Guler M; Tosun M; Ulgen M; Tan U Int J Neurosci; 2002 Jul; 112(7):817-28. PubMed ID: 12424822 [TBL] [Abstract][Full Text] [Related]
34. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Kasper S Int Clin Psychopharmacol; 1998 Nov; 13(6):253-62. PubMed ID: 9861575 [TBL] [Abstract][Full Text] [Related]
35. Atypical antipsychotic drugs and long-term outcome in schizophrenia. Weiden P; Aquila R; Standard J J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171 [TBL] [Abstract][Full Text] [Related]